Letters

Thiazolidinediones for type 2 diabetes

BMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7280.235 (Published 27 January 2001) Cite this as: BMJ 2001;322:235

No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4

  1. N Bradly Glazer (bglazer@takedapharm.com), manager, scientific communications,
  2. Wayman Wendell Cheatham, vice president, medical and regulatory
  1. Takeda Pharmaceuticals America, 475 Half Day Road, Suite 500, Lincolnshire, IL 60069, USA
  2. Clinical Research and Development and Medical Affairs UK, SmithKlineBeecham Pharmaceuticals, Mundells, Welwyn Garden City, Hertfordshire AL7 1EY

    EDITOR—In their editorial on thiazolidinediones for type 2 diabetes Krentz et al incorrectly stated: “Pioglitazone induces cytochrome P450 isoform CYP3A4, raising the possibility of drug interactions, such as with oral contraceptives.”1 No supporting documentation was provided for this statement.

    Ishida et al recently evaluated the relation between the therapeutic effects of troglitazone and pioglitazone in steroid induced diabetes.2 Urinary excretion of 6β-hydroxycortisol and the ratio of 6β-hydroxycortisol to cortisol were measured as a marker of CYP3A4 induction. Urinary excretion of 6β-hydroxycortisol was significantly increased with treatment with troglitazone but remained unchanged with treatment with pioglitazone.

    The …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe